BSFA Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Cortrophin GrowthCortrophin is becoming a major growth platform, with expanding demand across multiple specialties and a larger commercial team. Sustained adoption could materially improve ANI’s revenue mix and support continued operating leverage.
Generics PipelineConsistent generic launches and in-house pharmaceutical capabilities provide recurring opportunities to replace mature products and broaden revenue. This pipeline also diversifies growth beyond Cortrophin and supports manufacturing scale.
Balance SheetStrong operating cash generation, substantial liquidity and reduced net leverage improve ANI’s financial flexibility. The healthier capital structure can support product investment, business development and execution through operating volatility.
Bears Say
Cortrophin Timing RiskAlthough Cortrophin remains a strong growth driver, the guidance adjustment shows that demand conversion and timing are not fully predictable. Continued execution or access friction could make results more dependent on one product.
Margin PressureHigher manufacturing costs and investment in the expanded gout sales force are absorbing part of the revenue benefit. If these expenses persist faster than product growth, margin expansion and earnings conversion could remain constrained.
Earnings ConsistencyThe historical losses and weaker recent cash-flow growth indicate that profitability is not yet consistently resilient. Working-capital effects, one-time items or cost swings could reduce the reliability of reported earnings and cash generation.
ANI Pharmaceuticals News
BSFA FAQ
What was ANI Pharmaceuticals Inc’s price range in the past 12 months?
Currently, no data Available
What is ANI Pharmaceuticals Inc’s market cap?
ANI Pharmaceuticals Inc’s market cap is CHF1.32B.
When is ANI Pharmaceuticals Inc’s upcoming earnings report date?
ANI Pharmaceuticals Inc’s upcoming earnings report date is Nov 11, 2026 which is in 58 days.
How were ANI Pharmaceuticals Inc’s earnings last quarter?
ANI Pharmaceuticals Inc released its earnings results on Aug 07, 2026. The company reported CHF1.806 earnings per share for the quarter, beating the consensus estimate of CHF1.67 by CHF0.136.
Is ANI Pharmaceuticals Inc overvalued?
According to Wall Street analysts ANI Pharmaceuticals Inc’s price is currently Undervalued.
Does ANI Pharmaceuticals Inc pay dividends?
ANI Pharmaceuticals Inc does not currently pay dividends.
What is ANI Pharmaceuticals Inc’s EPS estimate?
ANI Pharmaceuticals Inc’s EPS estimate is 1.77.
How many shares outstanding does ANI Pharmaceuticals Inc have?
ANI Pharmaceuticals Inc has 22,959,488 shares outstanding.
What happened to ANI Pharmaceuticals Inc’s price movement after its last earnings report?
ANI Pharmaceuticals Inc reported an EPS of CHF1.806 in its last earnings report, beating expectations of CHF1.67. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of ANI Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in CH:BSFA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ANI Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF89.79 (― Upside)
CHF89.79 (― Upside)
Blogger Sentiment
Neutral
CH:BSFA Sentiment 57%
Sector Average 62%
Sector Average 62%
Insider Transactions
Sold Shares
Worth CHF196.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.90%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
11.25%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
ANI Pharmaceuticals Inc
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
BSFA Company Deck
BSFA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong operational execution with record Q2 revenue, record adjusted EBITDA, robust Cortrophin momentum, a major sales force expansion, continued generics execution and a healthy balance sheet. Near-term headwinds include timing-related adjustments (modest Cortrophin guidance revision), higher cost of sales and increased SG&A from the gout expansion, and a Q3 EBITDA sequential dip tied to milestone timing and fully loaded expansion costs. Management emphasizes continued confidence in multi-year Cortrophin growth and reaffirmed full-year company guidance, indicating that the positives (growth, margin expansion outlook, cash generation and strategic progress) meaningfully outweigh the short-term operational and timing challenges.View all CH:BSFA earnings summariesBSFA Stock 12 Month Forecast
Average Price Target
――
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Harrow Health
―